Effective treatments for opioid addiction | national institute on drug abuse (NIDA). https://nida.nih.gov/publications/effective-treatments-opioid-addiction

Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–45.

Article  PubMed  PubMed Central  Google Scholar 

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020. https://doi.org/10.1001/jamanetworkopen.2019.20622.

Article  PubMed  Google Scholar 

Sullivan LE, Fiellin DA. Buprenorphine Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clinical Infectious Diseases. 2005;41(6):891–6.

Article  CAS  PubMed  Google Scholar 

Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O’Connor PG, Weiss L, et al. The impact of buprenorphine/naloxone treatment on hiv risk behaviors among HIV-infected opioid-dependent patients. Drug Alcohol Depend. 2014;139:79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O’Connor PG, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92.

Article  PubMed  Google Scholar 

Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists and others. Health Aff. 2020;9(6):984–92.

Article  Google Scholar 

Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87–92.

Article  PubMed  Google Scholar 

Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019;321(14):1407–8.

Article  PubMed  PubMed Central  Google Scholar 

Medicated-Assisted Treatment Training Materials & Resources | SAMHSA. https://www.samhsa.gov/medications-substance-use-disorders/training-resources

Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the US?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.

Article  PubMed  Google Scholar 

Lanham HJ, Papac J, Olmos DI, Heydemann EL, Simonetti N, Schmidt S, et al. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver. JAMA Netw Open. 2022;5(5):e2212419–e2212419.

Article  PubMed  PubMed Central  Google Scholar 

Medications for opioid use disorder save lives. medications for opioid use disorder save lives. 2019 May 16.

Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):761–8.

Article  PubMed  Google Scholar 

Keller CE, Ashrafioun L, Neumann AM, Van Klein J, Fox CH, Blondell RD. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. Subst Abus. 2012;33(2):103–13.

Article  PubMed  Google Scholar 

Jamison RN, Scanlan E, Matthews ML, Jurcik DC, Ross EL. Attitudes of primary care practitioners in managing chronic pain patients prescribed opioids for pain: a prospective longitudinal controlled trial. Pain Med. 2016;7(1):99–113.

Google Scholar 

Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Subst Abuse Rehabil. 2022. https://doi.org/10.2147/SAR.S304566.

Article  PubMed  PubMed Central  Google Scholar 

Van Boekel LC, Brouwers EPM, Van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1–2):23–35.

Article  PubMed  Google Scholar 

Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: What role does stigma play? Subst Abus. 2019;40(4):459–65.

Article  PubMed  Google Scholar 

Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181–201.

Article  PubMed  Google Scholar 

Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Dependence Rep. 2023;6: 100138.

Article  Google Scholar 

Dickson-Gomez J, Spector A, Weeks M, Galletly C, McDonald M, Green Montaque HD. You’re not supposed to be on it forever”: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse. 2022. https://doi.org/10.1177/11782218221103859.

Article  PubMed  PubMed Central  Google Scholar 

Avery J, Dixon L, Adler D, Oslin D, Hackman A, First M, et al. Psychiatrists attitudes toward individuals with substance use disorders and serious mental illness. J Dual Diagn. 2013;9(4):322–6.

Article  Google Scholar 

Kennedy-Hendricks A, Busch SH, McGinty EE, Bachhuber MA, Niederdeppe J, Gollust SE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016. https://doi.org/10.1016/j.drugalcdep.2016.05.010.

Article  PubMed  PubMed Central  Google Scholar 

Baker R, Camosso-Stefinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 1996. https://doi.org/10.1002/14651858.CD005470.pub2.

Article  Google Scholar 

How to Address COVID-19 Vaccine Misinformation | CDC. https://www.cdc.gov/vaccines/covid-19/health-departments/addressing-vaccine-misinformation.html

Garett R, Young SD. The role of misinformation and stigma in opioid use disorder treatment uptake. Subst Use Misuse. 2022;57(8):1332–6.

Article  PubMed  PubMed Central  Google Scholar 

Suboxone VJR. Rationale, science, misconceptions. Ochsner J. 2018;18(1):23.

Google Scholar 

Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.

Article  PubMed  Google Scholar 

Brousseau NM, Farmer H, Karpyn A, Laurenceau JP, Kelly JF, Hill EC, et al. Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences. J Subst Abuse Treat. 2022;132: 108593.

Article  CAS  PubMed  Google Scholar 

Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019. https://doi.org/10.1186/s12875-019-1047-z.

Article  PubMed  PubMed Central  Google Scholar 

Muzyk A, Smothers ZPW, Akrobetu D, Ruiz Veve J, MacEachern M, Tetrault JM, et al. Substance use disorder education in medical schools: a scoping review. Acad Med. 2019;94(11):1825–34.

Article  PubMed  Google Scholar 

Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):1002969. https://doi.org/10.1371/journal.pmed.1002969.

Article  Google Scholar 

Care I of M (US) C on the F of P, Donaldson MS, Yordy KD, Lohr KN, Vanselow NA. 1996. Defining primary care. https://www.ncbi.nlm.nih.gov/books/NBK232631/

Franz B, Dhanani LY, Brook DL. Physician blame and vulnerability: novel predictors of physician willingness to work with patients who misuse opioids. Addict Sci Clin Pract. 2021;16(1):1–9. https://doi.org/10.1186/s13722-021-00242-w.

Article  Google Scholar 

Franz B, Dhanani LY, Miller WC. Rural-Urban differences in physician bias toward patients with opioid use disorder. Psychiatr Serv. 2021;72(8):874–9.

Article  PubMed  Google Scholar 

Ohio Rural Health Improvement Plan—Ohio rural health association. https://www.ohioruralhealth.org/ohio-rural-health-improvement-plan

Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Rep. 2023;6: 100133.

Article  Google Scholar 

Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359–62.

Article  PubMed  PubMed Central  Google Scholar 

Madden EF, Barker KK, Guerra J, Villanueva C, Sulzer SH. Variation in intervention stigma among medications for opioid use disorder. SSM—Qual Res Health. 2022;1(2): 100161.

Article  Google Scholar 

Walter N, Brooks JJ, Saucier CJ, Suresh S. Evaluating the impact of attempts to correct health misinformation on social media: a meta-analysis. Health Commun. 2021;36(13):1776–84.

Article  PubMed  Google Scholar 

Americans trust in scientists, other groups declines | pew research center. https://www.pewresearch.org/science/2022/02/15/americans-trust-in-scientists-other-groups-declines/